229 related articles for article (PubMed ID: 19597911)
1. Of mice and men: divergent risks of teriparatide-induced osteosarcoma.
Subbiah V; Madsen VS; Raymond AK; Benjamin RS; Ludwig JA
Osteoporos Int; 2010 Jun; 21(6):1041-5. PubMed ID: 19597911
[TBL] [Abstract][Full Text] [Related]
2. Safety of parathyroid hormone for the treatment of osteoporosis.
Miller PD
Curr Osteoporos Rep; 2008 Mar; 6(1):12-6. PubMed ID: 18430395
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide in individuals with a prior history of radiation therapy-a case series.
Cheung YM; Hamnvik OR
Arch Osteoporos; 2021 Oct; 16(1):149. PubMed ID: 34608566
[TBL] [Abstract][Full Text] [Related]
4. Probable osteosarcoma risk after prolonged teriparatide treatment: comment on the article by Saag et al.
Tastekin N; Zateri C
Arthritis Rheum; 2010 Jun; 62(6):1837; author reply 1837-8. PubMed ID: 20191586
[No Abstract] [Full Text] [Related]
5. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.
Gilsenan A; Midkiff K; Harris D; Kellier-Steele N; McSorley D; Andrews EB
J Bone Miner Res; 2021 Feb; 36(2):244-251. PubMed ID: 32990990
[TBL] [Abstract][Full Text] [Related]
6. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.
Kellier-Steele N; Casso D; Anderson A; Oliveria SA; Motsko S
Bone; 2022 Jul; 160():116394. PubMed ID: 35318162
[TBL] [Abstract][Full Text] [Related]
7. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
8. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years.
Gilsenan A; Harding A; Kellier-Steele N; Harris D; Midkiff K; Andrews E
Osteoporos Int; 2018 Oct; 29(10):2335-2343. PubMed ID: 29978254
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human parathyroid hormone. Preclinical data on rat osteosarcoma were not dismissed.
Kuijpers G; Schneider B; Stadel B; Colman E
BMJ; 2002 May; 324(7347):1218; author reply 1218. PubMed ID: 12016199
[No Abstract] [Full Text] [Related]
10. Present at the beginning: a personal reminiscence on the history of teriparatide.
Marcus R
Osteoporos Int; 2011 Aug; 22(8):2241-8. PubMed ID: 21452026
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
[TBL] [Abstract][Full Text] [Related]
12. Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report.
Javinani A; Aghaei Meybodi HR; Kavosi H
J Med Case Rep; 2020 Jul; 14(1):87. PubMed ID: 32616027
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide: a review.
Quattrocchi E; Kourlas H
Clin Ther; 2004 Jun; 26(6):841-54. PubMed ID: 15262455
[TBL] [Abstract][Full Text] [Related]
14. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
15. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.
Andrews EB; Gilsenan A; Midkiff K; Harris D
Ann Epidemiol; 2016 Nov; 26(11):751-753. PubMed ID: 27645108
[No Abstract] [Full Text] [Related]
16. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
[TBL] [Abstract][Full Text] [Related]
17. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
18. Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide.
Elraiyah T; Gionfriddo MR; Murad MH
J Clin Epidemiol; 2015 Jun; 68(6):698-702. PubMed ID: 25766055
[TBL] [Abstract][Full Text] [Related]
19. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data.
Gilsenan A; Midkiff K; Harris D; McQuay L; Hunter S; Kellier-Steele N; Andrews E
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1616-1626. PubMed ID: 32894794
[TBL] [Abstract][Full Text] [Related]
20. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
Dobnig H
Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
